Skip to content

Kaempferol alleviates myocardial ischemia-reperfusion injury by activating the Nrf2/GPX4 signaling pathway to inhibit ferroptosis.

Jul 2026 · European Journal of Pharmacology · pp. 179198 · 0 citations · 54 references
Medicine

TL;DR

It is demonstrated that kaempferol ameliorates MIRI by activating Nrf2/GPX4-related antioxidant signaling, thereby inhibiting ferroptosis, attenuating apoptosis, reducing myocardial structural damage, and ultimately preserving cardiac function.

Abstract

Myocardial ischemia-reperfusion injury (MIRI) remains a major cause of myocardial dysfunction after reperfusion therapy, and effective pharmacological interventions are still limited. Ferroptosis plays a pivotal role in MIRI pathogenesis. This study investigated whether kaempferol, a natural flavonoid, protects against MIRI by activating nuclear factor erythroid 2-related factor 2 (Nrf2)/glutathione peroxidase 4 (GPX4)-mediated ferroptosis defense. In male C57BL/6 mice subjected to left anterior descending coronary artery ligation/reperfusion, kaempferol reduced myocardial infarct size, preserved cardiac contractile function, decreased serum cardiac injury markers, and attenuated myocardial fibrosis and apoptosis. In H9c2 cardiomyocytes exposed to hypoxia/reoxygenation (HR), kaempferol improved cell viability and reduced the expression of cleaved caspase-3 and cleaved PARP. Mechanistically, kaempferol restored antioxidant capacity, alleviated lipid peroxidation and iron overload, and preserved mitochondrial membrane potential. Non-targeted metabolomics revealed that kaempferol modulated glutamate/glutamine metabolism, glycerophospholipid metabolism, and glutathione-related pathways. Furthermore, kaempferol was able to reverse MIRI/HR-induced suppression of Nrf2, solute carrier family 7 member 11 (SLC7A11), and GPX4, inhibit RAS-selective lethal 3 (RSL3)-induced ferroptosis, and increase phosphorylation of Nrf2 at Ser40. Molecular docking analysis suggested that kaempferol may interact with the Nrf2-binding pocket of its repressor protein, implying a potential upstream mechanism for Nrf2 activation. Importantly, the Nrf2 inhibitor ML385 markedly weakened the protective and anti-ferroptotic effects of kaempferol. Collectively, these findings demonstrate that kaempferol ameliorates MIRI by activating Nrf2/GPX4-related antioxidant signaling, thereby inhibiting ferroptosis, attenuating apoptosis, reducing myocardial structural damage, and ultimately preserving cardiac function.

View source

Similar papers

Sep 2026

NAMPT activation protects against myocardial ischemia/reperfusion injury via FSP1-CoQ10 ferroptosis defense.

BACKGROUND Myocardial ischemia/reperfusion injury (MIRI) is characterized by metabolic disturbance, oxidative stress, mitochondrial dysfunction and regulated cardiomyocyte death. Nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme of the NAD+ salvage pathway, plays an important role in redox metabo...

Xiao-Dong Wang, Chang Liu, Jie Wang et al. · 0 citations
Aug 2026

4-Octyl itaconate attenuates cerebral ischemia reperfusion injury by mitigating mitochondrial dysfunction mediated neuronal apoptosis and ferroptosis via the Nrf2/HO-1/SLC7A11/GPX4 axis.

Ischemic stroke is an unmet therapeutic need, characterised by excessive oxidative stress, mitochondrial impairment, blood-brain barrier (BBB) damage, and neuronal cell death. 4-Octyl itaconate (4-OI) is known for its promising antioxidant properties; however, its effects in cerebral ischemia/reperfusion (I/R) injury h...

Chandan Chauhan, Ravinder K. Kaundal · 0 citations
Open access Aug 2026

Sevoflurane Alleviates Myocardial Ischemia‐Reperfusion Injury via the HMGB1/ACSL4 Pathway to Suppress Ferroptosis

Sevoflurane (sevo) exhibits cardioprotective effects against myocardial ischemia/reperfusion injury (MIRI); however, its precise molecular mechanism of action remains elusive and warrants further in‐depth investigation. A rat model of MIRI and a hypoxia/reoxygenation (H/R) model in the H9c2 cardiomyocytes were establis...

Yuliu Mei, Yunfei Cao, Cheng Sheng et al. · 0 citations
Review Open access Sep 2026

Role of ALDH2 in myocardial ischemia-reperfusion injury: using ALDH2 as a potential therapeutic target.

Myocardial ischemia-reperfusion (I/R) injury remains a major barrier to the full benefit of timely coronary reperfusion. This review summarizes the role of mitochondrial aldehyde dehydrogenase 2 (ALDH2) as both an endogenous cardioprotective enzyme and a potential therapeutic target in myocardial I/R injury. During rep...

Meng Sun, Zhi-Xiong Gao, Feng-Yan Hu et al. · 0 citations
Open access Jul 2026

C3aR inhibition alleviates cerebral ischemia-reperfusion injury via STING-mediated ferroptosis through SLC7A11/GPX4

Summary Cerebral ischemia-reperfusion injury couples complement activation with innate immune signaling and ferroptotic lipid peroxidation. We investigated whether C3aR signaling modulates stimulator of interferon genes (STING)-associated ferroptosis through the solute carrier family 7 member 11 (SLC7A11)/glutathione p...

Yi-Feng Zhang, Yulei Xia, Zimeng Chen et al. · 0 citations
Open access Aug 2026

P38α deficiency alleviates myocardial ischemia/reperfusion injury by stabilizing c‑Myc to inhibit ferroptosis

Myocardial ischemia/reperfusion (I/R) injury constitutes a major clinical challenge in ischemic heart disease, and ferroptosis has been recognized as a core driver of cardiomyocyte death during reperfusion. However, the upstream regulatory network governing myocardial ferroptosis remains incompletely defined. The mitog...

Xiao-Hu S. Ouyang, Shu-Xin Song, Ya-Lan Dong et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.